SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-800-750-9692.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If information provided is not complete, correct, or legible, authorization may be delayed.**

Drug Requested: Cimzia® SQ (certolizumab) **(Pharmacy)**

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

DEA OR NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy:** _____

Diagnosis: _____ **ICD Code:** _____

Weight: _____ **Date:** _____

NOTE: The Health Plan considers the use of concomitant therapy with more than one biologic immunomodulator (e.g., Dupixent, Entyvio, Humira, Rinvoq, Stelara) prescribed for the same or different indications to be experimental and investigational. Safety and efficacy of these combinations has **NOT** been established and will **NOT** be permitted.

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied. **Check the diagnosis below that applies.**

❑ Diagnosis: Moderate-to-Severe Crohn's disease (CD)

- ❑ Member has a diagnosis of moderate-to-severe **Crohn's disease**
- ❑ Prescribed by or in consultation with a **Gastroenterologist**

(Continued on next page)

- ❑ Member meets **ONE** of the following:
  - ❑ Member has tried and failed budesonide or high dose steroids (40-60 mg prednisone)
  - ❑ Member has tried and failed at least **ONE** of the following **DMARD** therapies for at least **three (3) months**
    - ❑ 5-aminosalicylates (balsalazide, olsalazine, sulfasalazine)
    - ❑ oral mesalamine (Apriso, Asacol/HD, Delzicol, Lialda, Pentasa)
- ❑ Member meets **ONE** of the following:
  - ❑ Member tried and failed, has a contraindication, or intolerance to **ONE** of the following **PREFERRED** adalimumab products:
    - ❑ Humira®
    - ❑ Cyltezo®
    - ❑ Hyrimoz®

    ***NOTE:** Humira NDC's starting with 83457 are not approved, NDC's starting with 00074 (MFG: Abbvie) are preferred; Hyrimoz NDC's starting with 83457 are not approved, NDC's starting with 61314 (MFG: Sandoz) are preferred
  - ❑ Member has been established on Cimzia® for at least 90 days **AND** prescription claims history indicates **at least a 90-day supply of Cimzia was dispensed within the past 130 days (verified by chart notes or pharmacy paid claims)**

❑ Diagnosis: Active Psoriatic Arthritis

- ❑ Member has a diagnosis of active **psoriatic arthritis**
- ❑ Prescribed by or in consultation with a **Rheumatologist**
- ❑ Member has tried and failed at least **ONE** of the following **DMARD** therapies for at least **three (3) months**
  - ❑ cyclosporine
  - ❑ leflunomide
  - ❑ methotrexate
  - ❑ sulfasalazine

(Continued on next page)

- ❑ Member meets **ONE** of the following:
  - ❑ Member tried and failed, has a contraindication, or intolerance to **TWO** of the **PREFERRED** biologics below **(verified by chart notes or pharmacy paid claims):**

❑ adalimumab product: Humira®, Cyltezo® or Hyrimoz®	❑ Enbrel®	❑ Otezla®	❑ Rinvoq®
	❑ Skyrizi®	❑ Stelara®	❑ Taltz®
	❑ Tremfya®	❑ Xeljanz®/XR®	

***NOTE:** Humira NDC's starting with 83457 are not approved, NDC's starting with 00074 (MFG: Abbvie) are preferred; Hyrimoz NDC's starting with 83457 are not approved, NDC's starting with 61314 (MFG: Sandoz) are preferred

  - ❑ Member has been established on Cimzia® for at least 90 days AND prescription claims history indicates **at least a 90-day supply of Cimzia was dispensed within the past 130 days (verified by chart notes or pharmacy paid claims)**

❑ Diagnosis: Moderate-to-Severe Rheumatoid Arthritis

- ❑ Member has a diagnosis of moderate-to-severe **rheumatoid arthritis**
- ❑ Prescribed by or in consultation with a **Rheumatologist**
- ❑ Member has tried and failed at least **ONE** of the following **DMARD** therapies for at least **three (3) months**
  - ❑ hydroxychloroquine
  - ❑ leflunomide
  - ❑ methotrexate
  - ❑ sulfasalazine
- ❑ Member meets **ONE** of the following:
  - ❑ Member tried and failed, has a contraindication, or intolerance to **TWO** of the **PREFERRED** biologics below (verified by chart notes or pharmacy paid claims):

❑ Actemra® SC	❑ adalimumab product: Humira®, Cyltezo® or Hyrimoz®	❑ Enbrel®
❑ Rinvoq®	❑ Xeljanz®/XR®	

***NOTE:** Humira NDC's starting with 83457 are not approved, NDC's starting with 00074 (MFG: Abbvie) are preferred; Hyrimoz NDC's starting with 83457 are not approved, NDC's starting with 61314 (MFG: Sandoz) are preferred

  - ❑ Member has been established on Cimzia® for at least 90 days AND prescription claims history indicates **at least a 90-day supply of Cimzia was dispensed within the past 130 days (verified by chart notes or pharmacy paid claims)**

(Continued on next page)

❑ Diagnosis: Active Non-Radiographic Axial Spondyloarthritis

- ❑ Member has a diagnosis of active non-radiographic **axial spondyloarthritis**
- ❑ Prescribed by or in consultation with a **Rheumatologist**
- ❑ Member has at least **ONE** of the following objective signs of inflammation:
  - ❑ C-reactive protein [CRP] levels above the upper limit of normal
  - ❑ Sacroiliitis on magnetic resonance imaging [MRI] (indicative of inflammatory disease, but without definitive radiographic evidence of structural damage on sacroiliac joints)
- ❑ Member tried and failed, has a contraindication, or intolerance to **TWO** NSAIDs

❑ Diagnosis: Ankylosing Spondylitis

- ❑ Member has a diagnosis of **ankylosing spondylitis**
- ❑ Prescribed by or in consultation with a **Rheumatologist**
- ❑ Member tried and failed, has a contraindication, or intolerance to **TWO** NSAIDs
- ❑ Member meets **ONE** of the following:
  - ❑ Member tried and failed, has a contraindication, or intolerance to **TWO** of the **PREFERRED** biologics below **(verified by chart notes or pharmacy paid claims)**:

❑ adalimumab product: Humira®, Cyltezo® or Hyrimoz®	❑ Enbrel®	❑ Rinvoq®
❑ Taltz®	❑ Xeljanz®/XR®	

***NOTE:** Humira NDC's starting with 83457 are not approved, NDC's starting with 00074 (MFG: Abbvie) are preferred; Hyrimoz NDC's starting with 83457 are not approved, NDC's starting with 61314 (MFG: Sandoz) are preferred

  - ❑ Member has been established on Cimzia® for at least 90 days **AND** prescription claims history indicates **at least a 90-day supply of Cimzia was dispensed within the past 130 days (verified by chart notes or pharmacy paid claims)**

❑ Diagnosis: Moderate-to-Severe Plaque Psoriasis

- ❑ Member has a diagnosis of moderate-to-severe **plaque psoriasis**
- ❑ Prescribed by or in consultation with a **Dermatologist**

(Continued on next page)

- ❑ Member tried and failed at least **ONE** of either Phototherapy or Alternative Systemic Therapy for at least **three (3) months (check each tried below):**

❑ **Phototherapy:** ❑ **UV Light Therapy** ❑ NB UV-B ❑ PUVA	❑ **Alternative Systemic Therapy:** ❑ **Oral Medications** ❑ acitretin ❑ methotrexate ❑ cyclosporine

- ❑ Member meets **ONE** of the following:
  - ❑ Member tried and failed, has a contraindication, or intolerance to **TWO** of the **PREFERRED** biologics below **(verified by chart notes or pharmacy paid claims):**

❑ adalimumab product: Humira®, Cyltezo® or Hyrimoz®	❑ Enbrel®	❑ Otezla®	❑ Skyrizi®
	❑ Stelara®	❑ Taltz®	❑ Tremfya®

  ***NOTE:** Humira NDC's starting with 83457 are not approved, NDC's starting with 00074 (MFG: Abbvie) are preferred; Hyrimoz NDC's starting with 83457 are not approved, NDC's starting with 61314 (MFG: Sandoz) are preferred

  - ❑ Member has been established on Cimzia® for at least 90 days **AND** prescription claims history indicates **at least a 90-day supply of Cimzia was dispensed within the past 130 days (verified by chart notes or pharmacy paid claims)**

Medication being provided by a Specialty Pharmacy – Proprium Rx

Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.*